Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Precision BioSciences, Inc. - Common Stock
(NQ:
DTIL
)
4.130
-0.070 (-1.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Precision BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
February 14, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
February 13, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
February 12, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Effect a Reverse Stock Split
February 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
January 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
December 13, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
December 04, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Hep-DART 2023
November 30, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 28, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
November 14, 2023
Via
ACCESSWIRE
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
November 13, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Upcoming Sidoti Conference
November 10, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 09, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Third Quarter Results on November 7, 2023
November 01, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
October 26, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
October 23, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
October 12, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
September 27, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
September 12, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
September 06, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
August 31, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
August 15, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 04, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter Results on August 4, 2023
August 01, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
July 27, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
June 22, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Upcoming June Investor Conferences
June 05, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
May 31, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
May 25, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.